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mohamedsaif.xlnc@Abstract Tizanidine hydrochloride (THCl) is an antispasmodic agent which undergoes extensive
ﬁrst pass metabolism making it a possible candidate for buccal delivery. The aim of this study was
to prepare a monolayered buccal patch containing THCl using the emulsiﬁcation solvent
evaporation method. Fourteen formulations were prepared using the polymers Eudragits RS
100 or Eudragits RL 100 and chitosan. Polymer solutions in acetone were combined with a THCl
aqueous solution (in some cases containing chitosan) by homogenization at 9000 rpm for 2 min in
the presence of triethyl citrate as plasticizer and cast in novel Teﬂon molds. Physicochemical
properties such as ﬁlm thickness, in vitro drug release and in vitro mucoadhesion were evaluated
after which permeation across sheep buccal mucosa was examined in terms of ﬂux and lag time.
Formulations prepared using a Eudragits polymer alone exhibited satisfactory physicomechanical
properties but lacked a gradual in vitro drug release pattern. Incorporation of chitosan into
formulations resulted in the formation of a porous structure which did exhibit gradual release of
drug. In conclusion, THCl can be delivered by a buccal patch formulated as a blend of Eudragits
and chitosan, the latter being necessary to achieve gradual drug release.
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Table 1 Relative amounts of Eudragits RS 100, Eudra-
gits RL 100 and chitosan (CHT) in patch formulations
based on THCl¼1.
Formulation Eudragits RS
100
Eudragits RL
100
CHT
F1 6 – –
F2 8 – –
F3 10 – –
F4 15 – –
F5 15 – 2
F6 15 – 1
F7 15 – 0.5
F8 – 6 –
F9 – 8 –
F10 – 10 –
F11 – 15 –
F12 – 15 2
F13 – 15 1
F14 – 15 0.5
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Buccal drug delivery is a highly effective way to improve
bioavailability. This is because the buccal mucosa has a rich
blood supply which facilitates direct entry of drug molecules
into the systemic circulation1,2. Buccal drug delivery is well
accepted by patients as the buccal cavity is easily accessible for
self-medication. In addition, buccal dosage forms allow drug
absorption to be rapidly terminated in case of an adverse
reaction. Formulations of buccal dosage forms include adhe-
sive tablets3,4, gels5,6 and patches7,8, of which patches are
preferable in terms of ﬂexibility and comfort9.
Tizanidine hydrochloride (THCl) is a centrally acting
a2-receptor agonist which regulates myotonolytic effects on
skeletal muscle10–12. It exhibits a short half-life of 2.5 h, a low
bioavailability of around 40% and a wide distribution in the
body. Tizanidine undergoes extensive ﬁrst pass metabolism
leading to breakdown of the imidazole ring and oxidation of
the aromatic ring and sulfur atom13. In an attempt to over-
come such extensive ﬁrst-pass metabolism, tizanidine was
selected as a candidate for formulation in a bioadhesive
buccal patch.
A bioadhesive THCl tablet for buccal delivery has been
formulated and evaluated by Shanker et al.14 and Giradkar
et al.15 but THCl buccal patches have not been investigated.
Buccal patches must be ﬂexible, elastic and strong to with-
stand the mechanical activity inside the mouth. They must also
possess good mucoadhesion in order to be retained in the
mouth for the desired duration. Buccal patches offer greater
ﬂexibility and comfort than adhesive tablets and a mono-
layered buccal patch was chosen for development in this study.
The patch was designed to provide unidirectional drug release,
a large contact surface area and good buccal penetration of
drug. Various formulation variables and their effect on
patch properties were evaluated. The hydrophobic polymers
Eudragits RS and RL-100 were used as base matrices and
chitosan (CHT) was incorporated as a hydrophilic polymer to
modify the rate of drug release16. Ethyl cellulose was used as
the backing layer17.2. Materials and methods
2.1. Materials
THCl was supplied by Endoc Pharma (India). CHT (MW:
110,000) was purchased from Marine Chemicals (Cochin,
India). Eudragits RS 100 and RL 100 were provided by
Vikram Thermo India Pvt Ltd. Acetone was purchased from
Sigma Aldrich (USA). Triethyl citrate was purchased from
Merck Specialties Pvt Ltd (India).
2.2. Preparation of patches
To prepare patches, the required quantity of Eudragits RS 100
or RL 100 was dissolved in acetone and 30% or 35% w/w
triethyl citrate (dry polymer weight), respectively added to the
acetone solutions. The required quantity of THCl was dissolved
in water and the acetone and aqueous solutions combined by
homogenization at 9000 rpm for 2 min. Finally 1 mL aliquots
of the resulting polymeric solution (4 mg/mL) were pipetted
into individual Teﬂon molds. Patches comprising differentratios of THCl, Eudragit and CHT were prepared as described
in Table 1. In patches containing CHT, CHT was dissolved in
the aqueous solution of THCl.
2.3. Evaluation of patches
2.3.1. Thickness and weight
The thickness of patches was assessed using a micrometer
screw gage (Mitutoyo, Japan). For each formulation, three
randomly selected patches with surface area 1 cm2 were used.
Each patch was weighed individually on an analytical balance
(Shimadzu, Japan) and the average weights calculated18.
2.3.2. Assay of THCl
A complete patch from a Teﬂon mold was cut into pieces and
crushed in a pestle and mortar under a water/ethanol solvent
system with continuous agitation. The contents were then
ﬁltered through a Whatman ﬁlter paper (Whatman Interna-
tional Ltd, England) into a volumetric ﬂask. After appropriate
dilution with phosphate buffer (pH 6.8), solutions were
analyzed by determination of absorption at 320 nm (UV
1800 spectrophotometer, Shimadzu, Japan) against a solvent
blank. Drug content was estimated from a calibration curve in
the range 2–12 mg/mL (regression equation Y¼0.050X,
R2¼0.9990).
2.3.3. Folding endurance
Folding endurance of patches was determined manually by
repeatedly folding a ﬁlm at the same place until it ruptures.
The number of folding required to break or crack a patch was
taken as the folding endurance19.
2.3.4. Surface pH
Patches were placed in glass tubes containing 10 mL phos-
phate buffer (pH 6.8) and the pH at the surface measured after
1, 2, 3, 4, 5, 6, 7 and 8 h by placing the tip of the glass
microelectrode of a digital pH meter (Elico LI 120, India)
close to the surface of the patch and allowing it to equilibrate
for 1 min prior to recording. Experiments were performed in
triplicate.
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Swelling and erosion of patches were determined under
conditions identical to those for the dissolution tests. The
degree of swelling (water uptake) and extent of erosion (mass
loss) were determined gravimetrically according to the equa-
tions20:
Degree of swelling¼ Wet weightoriginal dry weight
Original dry weight
ð1Þ
Erosionð%mass lossÞ
¼ Original weight2remaining dry weight
Original weight
 100% ð2Þ
2.3.6. In vitro drug release
Experiments were performed in triplicate using an orbital shaker
maintained at 3770.5 1C and 100 strokes per min. Patches were
ﬁrmly secured in modiﬁed glass bottles (125 mL) placed on the
shaker platform and 100 mL phosphate buffered saline (PBS, pH
6.8) added as the dissolution medium. At speciﬁed times, 2 mL
aliquots were removed using a syringe and replaced with equal
volumes of fresh PBS to maintain the total volume. Samples
were ﬁltered through a 0.45 mm Millipores Filter (Whatman
International Ltd, England) and THCl concentration determined
by measuring absorbance at 320 nm.2.3.7. Kinetics of drug release
The ﬁt of the drug release data to the Higuchi expression was
evaluated. According to this model, the cumulative amount of
drug released per unit area is proportional to the square root
of time:
Q¼ kHt1=2 ð3Þ
where Q is the amount of drug released after time t and kH is
the release rate constant.2.3.8. Scanning electron microscopy (SEM)
The cross section of dried ﬁlms was examined using a scanning
electron microscope (JEOL, JSM 840, Japan) after coating the
dried ﬁlms with gold sputter.Figure 1 Modiﬁed physical balance use2.3.9. In vitro mucoadhesion
The mucoadhesive strength of patches was measured in triplicate
on a modiﬁed physical balance (Fig. 1) using the method
described by Gupta et al.21. A piece of sheep buccal mucosa
was tied to the mouth of a glass vial ﬁlled completely with PBS
pH 6.8. The glass vial was tightly ﬁtted in the center of a beaker
ﬁlled with PBS at 3771 1C. Patches were stuck to the lower side
of rubber stoppers with glue and the mass (g) required to detach
the patches from the mucosal surface was taken as the mucoad-
hesive strength (shear stress). The following parameters were
calculated from the mucoadhesive strength:
Force of adhesion ðNÞ ¼ Mucoadhesive strength ðgÞ
1000
 9:81 ð4Þ
Bond Strength ðN=m2Þ ¼ Force of adhesion ðNÞ
Surface area ðm2Þ ð5Þ
2.3.10. In vitro permeability
The rate and extent of mucosal permeation of tizanidine through
sheep buccal mucosa was determined using a modiﬁed Franz
diffusion cell (Fig. 2). Brieﬂy, the receptor compartment (40 mL)
was ﬁlled with PBS (pH 6.8) at 3770.5 1C and stirred at 50 rpm.
The patch was sandwiched between the donor and receptor
compartments of the diffusion cell on the sheep buccal mucosa.
Aliquots (3 mL) of the receptor medium were withdrawn at
regular intervals and replaced immediately with equal volumes
of PBS (pH 6.8). The amount of tizanidine released into the
receptor medium was determined by measurement of absorption
at 320 nm against a blank.
2.3.11. Statistical analysis
Statistical analysis of all data was carried out using GraphPad
prism version 5.0 (Graphpad software Inc, San Diego,
California, USA).3. Results and discussion
Initially various hydrophobic polymers were examined for
ﬁlm forming properties and drug release characteristics.
After extensive preliminary investigation, Eudragits RS 100
and Eudragits RL 100 were identiﬁed as hydrophobicd to measure mucoadhesive strength.
Figure 2 Schematic representation of the modiﬁed Franz diffusion cell used to determine permeation of tizanidine across sheep buccal
mucosa.
Figure 3 Drug release from buccal patch formulations: (A)
Eudragits RS 100 and Eudragits RS 100-CHT formulations;
(B) Eudragits RL 100 and Eudragits RL 100-CHT formulations.
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release was retarded. However, initial drug release was rapid
rather than gradual as desired. Incorporation of CHT, a
hydrophilic polymer, is able to enhance drug release in a
concentration-dependent manner by promoting disintegration
of the polymer matrix22. In addition, it acts as a permeation
enhancer and enzyme inhibitor23,24. Based on these unique
properties, CHT was incorporated into patch formulations to
hopefully provide more controlled drug release.
The weight and thickness of patches were in the ranges 103.17
0.02 to 136.270.03 mg and 0.5370.03 to 0.6470.01 mm, respec-
tively. Folding endurance ranged from 81 foldings for formulation
F1 to 92 foldings for F11 (92) indicating patches were highly
ﬂexible. Drug content (%) of formulations varied from
98.9670.18 to 99.1970.11% indicating drug was dispersed
uniformly throughout the patches.
3.1. In vitro release
Initially THCl homopolymeric patches were made from either
Eudragits RS 100 or RL 100 and their in vitro drug release
was investigated. Patches made with THCl:Eudragits ratios
between 1:1 and 1:5 exhibited insufﬁcient mechanical strength
to be handled. Patches made with ratios between 1:6 and 1:15,
showed decreased drug release with distinct differences in drug
release proﬁles (Fig. 3). In particular, patches made with a
1:15 ratio of either Eudragits exhibited signiﬁcantly retarded
drug release which was greater for Eudragits RS 100 than for
RL 100. This could be attributed to the greater hydrophobi-
city of Eudragits RS 100 causing THCl to diffuse more slowly
into the dissolution medium. It could also be due to the
greater chloride ion content of Eudragits RL 100 allowing
more ion exchange with ions in the dissolution medium
leading to faster drug release. On the basis of these results,
it was concluded that a 1:15 ratio of THCl to Eudragits
provided the most controlled release of THCl with 40% being
released after 1 h and 100% after 8 h. In an attempt to reduce
the extent of release during the ﬁrst hour, a hydrophilic
polymer was incorporated into the formulation.
Although CHT and Eudragits possess very different solu-
bilities, a homogeneous formulation with a uniform distribution
of THCl was successfully prepared after emulsiﬁcation. Thisnovel method of preparation of a ﬁlm overcomes the problems
of content uniformity commonly encountered with conven-
tional multilayered ﬁlms. The addition of triethyl citrate also
plays a prominent role in ﬁlm formation since, in addition to
Mohamed S. Pendekal, Pramod K. Tegginamat322acting as a plasticizer, triethyl citrate also acts as an emulsifying
agent. Increasing the amount of triethyl citrate relative to CHT
does not lead to phase separation but can result in a mono-
layered ﬁlm with rigidity problems.
The purpose of incorporation of CHT was to reduce the initial
drug release and maintain the duration of drug release. The
addition of CHT to patches made with both Eudragits polymers
at ratios of 0.5:1 and 1:1 did not provide a more gradual initial
release pattern but addition of CHT at a 2:1 ratio (formulations
F5 and F12) produced the desired proﬁle. Presumably this
amount of CHT leads to the formation of pores in the polymer
matrix allowing the dissolution medium to freely penetrate,
solubilize the THCl and facilitate its escape22. To conﬁrm the
similarity of the dissolution proﬁles of F5 and F12, the similarity
factor (f2) was calculated and found to be 82.13 for F5 vs F12
and 83.45 for F12 vs F5. Since the f2 values are higher than 50,
these results conﬁrm that the drug release proﬁles are almost
identical for these formulations.3.2. Swelling and erosion
Swelling and erosion studies were conducted for formulations
F5 and F12 (Fig. 4). Eudragits is an insoluble, relatively
impermeable, cationic copolymer of acrylate and methacrylates
with quaternary ammonium groups and chloride counterions.
Its chemical name is poly(ethyl acrylate-co-methyl methacrylate-
co-trimethylammonioethyl methacrylate chloride). The onlyFigure 4 (A) Degree of swelling and (B) erosion of formulations
F5 and F12 over 8 h.difference between Eudragits RL and RS is the higher amount
of methacrylate chloride in Eudragits RL. Hydration and
swelling is governed by the chloride ions which undergo
exchange with the buffer anions in the dissolution medium to
increase hydration and swelling of the patches.
Formulations F5 and F12 undergo swelling in the ﬁrst hour
with degrees of swelling of 0.53 and 0.59, respectively. The
higher degree of swelling of formulation F12 is due to its
greater chloride ion content. Subsequently, only minor changes
in the degree of swelling took place attributed to the presence of
CHT in the formulations. In the dissolution medium, CHT in
the polymer leads to the formation of pores which, in turn,
reduce the swelling ability of the polymer. Swelling due to gel
formation does not occur at the acidic and near neutral pH of
CHT. In summary, the degree of swelling of patches suggests
they will cause minimal discomfort when in use.
Formulations F5 and F12 also exhibited marked reductions
in size after 1 h due to erosion. The values were 25.32%
erosion of formulation F5 and 27.22% erosion of formulation
F12 over 8 h. The erosion data conﬁrm that the patches
maintain their integrity throughout the period of drug release.
3.3. Kinetics of drug release
To interpret the release behavior of THCl from different patches,
it is necessary to ﬁt the data to a mathematical model. Although
various mathematical models are available, the Higuchi square
root model is the main one used to ﬁt the kinetics of drug release
from patches. Plotting of the data for formulations F5 and F12
gave correlation coefﬁcients of 0.939 and 0.924, respectively
conﬁrming that drug release occurred by diffusion through the
ﬁlm matrix. The values of kH were found to be 532.5 and
548.7 mg/(cm2 min1/2) for F5 and F12, respectively.
3.4. SEM
Formulations F5 and F12 were subjected to SEM studies to
assess changes in their surface morphology (Fig. 5). Initially
both formulations revealed smooth and compact surfaces but,
after 1 h, both formulations appeared porous particularly F5.
At 8 h, the surface of both formulations showed signiﬁcant
changes in texture and clearly visible pores. This may be due
to the uptake of water resulting from the presence of CHT in
the formulations. Based on these results, it can be concluded
that the presence of CHT in patches signiﬁcantly affects their
surface morphology and leads to the formation of pores in
accordance with the in vitro dissolution data.
3.5. Surface pH
The surface pH of a patch should be close to that of saliva
(i.e., 5.8–7.1) since deviation from this pH may cause irritation
to the oral mucosa. Values of surface pH for formulations F5
and F12 were in the range 6.2–6.5 indicating they are suitable
for application to the oral mucosa.
3.6. In vitro adhesion studies
The adhesion of patches to the oral mucosa is a prerequisite
for maintaining drug release. Formulation F5 was more
mucoadhesive than F12 possibly due to lower concentration
Figure 5 SEM photographs of formulations F5 and F12 after incubation in dissolution medium for up to 8 h.
Table 2 Results of the in vitro mucoadhesion study.
Formulation F5 F12
Mucoadhesive strength (g) 30.1271.14 28.7171.05
Force of adhesion (N) 0.3070.01 0.2870.02
Detachment force (N/m2) 167.2473.16 156.6272.82
Figure 6 In vitro drug permeation from formulations F5 and F12
over 8 h.
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F12, containing Eudragits RL 100 requires 35% w/w triethyl
citrate compared with 30% w/w in F5. The lower concentra-
tion of plasticizer reduces intermolecular attraction between
the polymers resulting in an additive mucoadhesive force
which, in turn, minimizes a polymer mucous interaction. The
higher amount of plasticizer utilized for the preparation of
patches may result in less mucoadhesivity but one-way
ANOVA of mucoadhesion data indicated no signiﬁcant
differences between formulations F5 and F12 (Table 2).
3.7. In vitro permeation studies
THCl permeation from formulations F5 and F12 across
sheep buccal mucosa over a period of 8 h is shown in Fig. 6.The maximum permeation of drug from F5 was 83.175.1% at
8 h compared with 80.171.1% from F12. Regression of the
linear portions of the two plots gave slopes and intercepts
from which the permeation ﬂux (slope divided by mucosal
surface area) of F5 and F12 were calculated to be 5.2770.41
and 5.1170.13 mg/cm2/h, respectively. The lag times for
Mohamed S. Pendekal, Pramod K. Tegginamat324formulations F5 and F12, determined by extrapolation of the
linear portions of the plots to the abscissa, were 1.2 and 1.3 h,
respectively. Formulation F5 made from Eudragits RS 100
gave higher permeation of drug than formulation F12 made
from Eudragits RL 100. In formulation F5, only one
methacrylate chloride ion is present which allows tizanidine
particles to pass from the formulation more easily than from
formulation F12 which contains more methacrylate ions to
hinder the passage of drug particles.4. Conclusions
THCl can be delivered by buccal patches formulated from
Eudragits and CHT polymers where the incorporation of
CHT is necessary to achieve a gradual release of drug.
Although formulations F5 and F12 exhibit such in vitro
release proﬁles, permeation of THCl from formulation F5
made with Eudragits RS 100 across buccal mucosa is
superior.
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